Fig. 2From: Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case reportResolution of extramedullary disease-associated lesions after treatment with LCAR-B38M CAR-T cell therapy. Baseline photo of patient’s extramedullary lesions on day 1 of the LEGEND-2 study (left), on day 19 (center), and after long-term follow-up (33 months) in March 2019 (right) showing clearance of extramedullary lesions. CAR, chimeric antigen receptorBack to article page